Cediranib completely inhibited the phosphorylation of FGFR2 and downstream targets, including FRS2, Akt, and MAPK, in GC cell lines (KATO-III and OCUM2M) that strongly expressed FGFR2-IIIb mRNA, and then significantly and dose-dependently inhibited tumor growth in KATO-III and OCUM2M tumor xenografts [46]. The gene discussed is AKT1; the disease is neoplasm.